Table 6.
Measure | Lead Author | Candidate Gene (MAF) | N (replication N) | Largest Effect |
---|---|---|---|---|
PPI | Petrovsky (2010)1 | CHRNA3 (0.35) | 107 (73) | 11.4% (7.5%) |
PPI | Quednow (2011)1 | TCF4 (0.06) | 107 (73) | 4.4% (12.1%) |
Startle reactivity | Roussos (2011)2 |
CACNA1C (0.27) ANK3 (0.04) |
445 | 9.55% 4.42% |
PPI | Roussos (2011)2 | NRG1 (0.37) | 445 | 2.65% |
PPI | Roussos (2011)2 | DAO (0.35) | 445 | 1.38% |
P50 | Quednow (2012)1 | TCF4 (0.06) | 1,821 | 0.91% |
P300 latency | Xu (2010) | miR-30e (0.03) | 2,190 | 0.63% |
SPEM (gain, saccade frequency) | Smyrnis (2011)3 | NRG1 (0.41) | 1,502 | 0.34% |
Antisaccade error SPEM | Kattoulos (2012)3 | RGS4 (0.48) | 1,530 | 0.33% |
Antisaccade error | Stefanis (2008)3 | RGS4 (0.48) | 1,532 | 0.20% |
P50 | Shaikh (2011) |
COMT (0.34) BDNF (0.17) NRG1 (0.36 – 0.39) |
451 |
—
— — |
P50 | Cabranes (2013) | CHRNA7 (0.27 – 0.49) | 375 | — |
Germany-Great Britain collaboration
Learning on Genetics of Schizophrenia (LOGOS)
Athens Study for Psychosis Proneness and Incidence of Schizophrenia (ASPIS)
Note: The MAF is given for each candidate gene studied where the published data permitted calculating it (i.e., if homozygotes for the rare allele were not combined with heterozygotes), or a range of MAFs if more than one SNP from a gene was examined. The column labeled “N (Replication N)” lists the number of subjects in each study, or in the Stage 1 sample if the study included a replication study. The number of subjects in the replication sample is provided in parentheses if applicable. The effect size of the largest association is provided in the last column, as a percentage of endophenotype variance accounted for. Associations that were not reported as statistically significant are indicated by a dash in place of the effect size. For studies including a replication sample (and analyzing discovery and replication samples separately), the variance accounted for in the replication by the variant is provided in parentheses.